Contact the Editorial Desk

Editorial correspondence

Aus Peptide welcomes correspondence on the research record itself: a citation quoted inaccurately, a newly published trial on CJC-1295, ipamorelin, MOTS-c, or sermorelin, or a regulatory update that changes how a compound's status should be described. This is the most useful category of message this desk receives, and each one is read carefully before any change is made to the site.

The most actionable submissions identify the specific page and passage in question and point to a supporting source — a DOI or PubMed identifier wherever possible — so the proposed correction can be verified against its origin before anything is edited.

Editorial mailbox: editors@auspeptide.com

What this desk cannot do

So a message doesn't go unanswered for the wrong reason, a few categories fall outside what Aus Peptide can address. This is a literature digest, not a clinical service, so it cannot:

• Recommend, evaluate, or comment on a dose, schedule, or route of administration for any individual.
• Advise on whether a research finding applies to a specific person's situation.
• Sell, source, or help locate any compound from any supplier.
• Advise athletes on anti-doping questions, though it will note where a compound is flagged by anti-doping authorities.

Sermorelin should be discussed only with a licensed prescriber; CJC-1295, ipamorelin, and MOTS-c have no approved human use and no clinical-supervision channel to direct a reader toward. Readers with clinical questions should consult a licensed healthcare provider in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.